Onsdag 5 Februari | 10:48:56 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2026-03-03 08:30 Bokslutskommuniké 2025
2025-11-04 08:30 Kvartalsrapport 2025-Q3
2025-08-12 08:30 Kvartalsrapport 2025-Q2
2025-05-13 N/A Årsstämma
2025-05-06 08:30 Kvartalsrapport 2025-Q1
2025-03-04 08:30 Bokslutskommuniké 2024
2024-11-05 - Kvartalsrapport 2024-Q3
2024-08-13 - Kvartalsrapport 2024-Q2
2024-05-15 - X-dag ordinarie utdelning CMOTEC B 0.00 SEK
2024-05-14 - Årsstämma
2024-05-07 - Kvartalsrapport 2024-Q1
2024-03-05 - Bokslutskommuniké 2023
2023-10-17 - Kvartalsrapport 2023-Q3
2023-08-15 - Kvartalsrapport 2023-Q2
2023-05-25 - Kvartalsrapport 2023-Q1
2023-05-17 - X-dag ordinarie utdelning CMOTEC B 0.00 SEK
2023-05-16 - Årsstämma
2023-03-07 - Bokslutskommuniké 2022
2022-11-22 - Kvartalsrapport 2022-Q3
2022-08-16 - Kvartalsrapport 2022-Q2
2022-05-25 - X-dag ordinarie utdelning CMOTEC B 0.00 SEK
2022-05-24 - Årsstämma
2022-05-03 - Kvartalsrapport 2022-Q1
2022-03-08 - Bokslutskommuniké 2021
2021-11-02 - Kvartalsrapport 2021-Q3
2021-08-17 - Kvartalsrapport 2021-Q2
2021-05-25 - X-dag ordinarie utdelning CMOTEC B 0.00 SEK
2021-05-24 - Årsstämma
2021-05-04 - Kvartalsrapport 2021-Q1
2021-03-08 - Bokslutskommuniké 2020
2020-11-11 - Kvartalsrapport 2020-Q3
2020-08-18 - Kvartalsrapport 2020-Q2
2020-05-20 - X-dag ordinarie utdelning CMOTEC B 0.00 SEK
2020-05-19 - Årsstämma
2020-05-13 - Kvartalsrapport 2020-Q1
2020-02-28 - Bokslutskommuniké 2019
2019-11-12 - Kvartalsrapport 2019-Q3
2019-08-12 - Kvartalsrapport 2019-Q2
2019-05-09 - X-dag ordinarie utdelning CMOTEC B 0.00 SEK
2019-05-08 - Årsstämma
2019-05-08 - Kvartalsrapport 2019-Q1
2019-03-19 - Extra Bolagsstämma 2019
2019-02-14 - Bokslutskommuniké 2018
2018-11-15 - Kvartalsrapport 2018-Q3
2018-08-15 - Kvartalsrapport 2018-Q2
2018-05-15 - Extra Bolagsstämma 2018
2018-05-15 - Kvartalsrapport 2018-Q1
2018-03-01 - X-dag ordinarie utdelning CMOTEC B 0.00 SEK
2018-02-28 - Årsstämma
2018-01-30 - Bokslutskommuniké 2017
2017-05-31 - Extra Bolagsstämma 2017

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Scandinavian ChemoTech är ett forsknings- och utvecklingsbolag som har tagit fram teknologin Tumörspecifik Elektroporation – TSE™ för behandling av olika cancerformer. Teknologin innebär att man skickar elektroniska pulser till det behandlade området och öppnar tumörcellernas membran för att nå deras DNA. Utöver sin verksamhet i Sverige är bolaget även aktivt i Sydostasien och Indien. Scandinavian ChemoTech grundades 2015 och har sitt huvudkontor i Lund.
2024-12-30 14:10:00

Since 2021, Scandinavian ChemoTech has operated two distinct business units - Human Care and Animal Care. While Human Care was the group's initial focus, the Board of Directors has made key decisions to support the independence and growth of the two separate entities. By separating the successful cash generating Animal Care unit from the more complex processes of Human Care, where much of the company's burn rate is concentrated, resources can be reallocated to boost sales activities within Animal Care. With these changes the company anticipates annual savings of 2-3 MSEK, which can be reallocated to revenue-generating activities within Animal Care.

Regulatory press release
Lund, Sweden 30 December 2024

To streamline the operations, the Board has decided to restructure the businesses using existing corporate entities. Animal Care will gradually transition from Sweden to its US subsidiary while also maintaining its strong sales performance in Central Europe under VQ Animal Care Inc. Additionally, the Human Care business will during 2025 move to the older entity Vetiqure AB, retaining the Scandinavian ChemoTech name, while the publicly listed holding company is set to adopt a new name.

These strategic changes reflect the company's commitment to enhancing revenue, improving profitability, and sustaining robust sales in key markets, particularly in US and Central Europe

New corp strucure

The Future pathway for TSE for Human Care in India, EU and USA
It is important to emphasize that the company's ambitions to revolutionize Human Care remain strong. However, the Board of Directors believes it is in the best interest of shareholders that Human Care operations to be funded through cash flows generated by Animal Care, rather than through new share issues.

 

Since the IQwave system is primarily designed for the treatment of superficial tumours, commonly seen in India and Asia, the regulatory focus will shift toward these regions. This strategy prioritizes cost-effective opportunities over the costly European regulatory processes, where the commercial potential for the current IQwave™ product remains limited. However, the future of TSE in the European market is envisioned to have a significant impact on cancer care as a laparoscopic or robotic solution. Our search and discussions with potential partners for technologies continues.

 

These changes will not impact our ambitions with our trial and collaboration with AIIMS Jodhpur in India.

 

For further information please contact:

Mohan Frick, CEO

 

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

 

Certified Adviser: Redeye AB

 

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 30-12-2024 14:10 CET.

 

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.